Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — Q3 FY2015 Earnings Presentation

24 slides from Daiichi Sankyo's earnings presentation, Jan 29, 2016

  1. Slide 1: Results Briefing: Results for Q3 FY2015

    Results Briefing Results for Q3 FY2015 (April 1 – December 31, 2015) DAIICHI SANKYO CO., LTD Joji Nakayama President and CEO January 29, 2016

  2. Slide 2: Today's Topics

    Today’s Topics  FY2015 Q3 YTD Results  FY2015 Revised Consolidated Forecast  Major Management Topics  Edoxaban Update in Japan and EU  R&D Update 1

  3. Slide 3: FY2015 Q3 YTD Results

    FY2015 Q3 YTD Results 2

  4. Slide 4: Overview of FY2015 Q3 YTD Results (JPY Bn)

    Overview of FY2015 Q3 YTD Results (JPY Bn) FY2014 Q3 YTD FY2015 Q3 YTD YoY Results *1 Results +9.2% Revenue 694.4 758.6 +64.2 Cost of Sales 220.9 237.7 +16.8 SG&A Expenses 237.8 232.3 -5.5 R&D Expenses 135.7 138.1 +2.4 +50.4% Operating Profit 100.0 150.4 +50.4 Profit before Tax 107.5 145.4 +38.0 +60

  5. Slide 5: Revenue

    Revenue Positive Negative Factors Factors Increased by 64.2 JPY Bn Decline in Daiichi Sankyo Europe offsetted by growth of Japan, Luitpold and ASCA with Forex (JPY Bn) FY2014 Results 694.4 Japan Japan (incl. Vaccines, OTC) 10.8 Positive: Lixana +7.5 Teneria +6.4 Nexium +6.2 Memary +5.2 Pralia +3.9 E

  6. Slide 6: Operating Profit

    Operating Profit Positive Negative Factors Factors Increased by 50.4 JPY Bn due to increased revenue, decreased SG&A expenses and special items absorbing increased other costs (JPY Bn) FY2014 Results 100.0 64.2 Revenue +64.2 Revenue 100.0 incl. forex impact 25.9 Cost of Sales 15.9 SG&A Expenses 148.

  7. Slide 7: Special Items

    Special Items (JPY Bn) FY2014 Q3 YTD Results FY2015 Q3 YTD Results YoY Restructuring costs in Japan 2.2 Gain on sales of subsidiary -2.4 Cost of Sales -5.7 Gain on sales of fixed assets- 1.1 Settlement expenses with US Department of Justice 4.6 SG&A Restructuring costs in US 6.1 Expenses Restructuri

  8. Slide 8: Profit attributable to owners of the Company

    Profit attributable to Positive Negative Factors Factors owners of the Company Increased by 41.8 JPY Bn due to increased operating profit Expenses relating to the sales of the Sun Pharma shares etc. are booked as financial expenses (JPY Bn) FY2014 Results 68.9 50.4 Operating Profit Financial Income

  9. Slide 9: Major Business Units

    Major Business Units (JPY Bn) FY2014 FY2015 vs. Forecast YoY Q3 YTD Results Q3 YTD Results (%) Japan 367.8 377.5 +9.6 76.9% Daiichi Sankyo Healthcare 37.0 39.9 +2.9 81.3% Daiichi Sankyo Inc. 126.2 145.5 +19.3 82.7% Olmesartan 76.9 88.4 +11.5 87.5% Welchol 35.1 37.7 +2.5 80.2% Effient 13.1 16.4 +3.3

  10. Slide 10: Major Products in Japan

    Major Products in Japan (JPY Bn) FY2014 FY2015 vs. Forecast Q3 YTD Q3 YTD YoY (%) Results Results Olmetec anti-hypertension 58.4 60.5 +2.1 76.6% 55.7 62.0 +6.2 80.5% anti-ulcer Nexium (Proton Pump Inhibitor) Memary treatment for Alzheimer 27.5 32.7 +5.2 69.6% Loxonin analgesic and anti-inflammatory

  11. Slide 11: FY2015 Revised Consolidated Forecast

    FY2015 Revised Consolidated Forecast 10

  12. Slide 12: FY2015 Revised Consolidated Forecast

    FY2015 Revised Consolidated Forecast (JPY Bn) FY 2015 FY 2015 vs. Forecast Revised Forecast Forecast Major factors (as of Oct.) (as of Jan.) (as of Oct.) Revenue 980.0 980.0 0 Cost of Sales 314.0 316.0 +2.0 Shift of product mix SG&A Expenses 354.0 337.0 -17.0 Efficient cost expense R&D Expenses 192.

  13. Slide 13: Major Management Topics

    Major Management Topics  Edoxaban Update in Japan and EU  R&D Update 12

  14. Slide 14: Japan: Lixiana

    Japan: Lixiana Impressive Market Share Growth M JPY (%) 16,000 Market Share: 12.9% 14 14,000 13 12,000 12 Product C 11 10,000 Product B 10 8,000 Product A 9 Lixiana 6,000 8 Lixiana (%) 4,000 7 2,000 6 0 5 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 ©2016 IMSHe

  15. Slide 15: EU: LIXIANA

    EU: LIXIANA Successful Step by Step Launches  Launched in Switzerland, UK, Germany, Ireland and Netherlands 000 EUR Germany: Monthly IMS sales from launch in SPAF 6,000 5,000 4,000 Product B 3,000 Product A Lixiana 2,000 Product C 1,000 0 Mth 1 Mth 2 Mth 3 Mth 4 ©2016 IMSHealth Calculated based on

  16. Slide 16: Major Management Topics

    Major Management Topics  Edoxaban Update in Japan and EU  R&D Update 15

  17. Slide 17: Biosimilar: Progress to launch on track

    Biosimilar: Progress to launch on track CHS-0214: Achieved Primary Endpoints in Phase 3 Study  CHS-0214: Etanercept biosimilar  Patients: Subjects with rheumatoid arthritis and inadequate response to treatment with methotrexate  Primary endpoint:  Efficacy CHS-0214 demonstrated similarity to Enb

  18. Slide 18: Oncology: Enrichment of pipeline

    Oncology: Enrichment of pipeline Accelerate Global Development  Quizartinib: FLT3-ITD inhibitor  Second-line treatment for Acute Myeloid Leukemia (QuANTUM-R Phase 3 study)  US and EU: on track  Asia: has started recruitment  First-line treatment for Acute Myeloid Leukemia  Global phase 3 study

  19. Slide 19: Oncology: Clinical Entries of New Biologics

    Oncology: Enrichment of pipeline Clinical Entries of New Biologics  DS-1123: Anti-FGFR2 antibody  High expression of FGFR2 is  U3-1784: Anti-FGFR4 antibody observed in gastric cancer etc.  High expression of FGFR4 is  Started phase 1 in Japan observed in hepatic cancer etc.  Started phase 1 in

  20. Slide 20: Biologics: Clinical entry of antibody alternative

    Biologics: Clinical entry of antibody alternative Value Creation by Combination of Innovative Technologies  Anticalin®  In-licensed technology from Pieris(US)  An alternative to antibody with molecular weight of 1/10  Low immunogenicity as compared to antibody  Can be produced by microorganism

  21. Slide 21: Anticipating Major R&D Milestone

    Anticipating Major R&D Milestone 【Milestone event for regulatory submission and approval】 Product Event Anticipated time Treatment of Pain and Opioid- CL-108 NDA FY2015 Q4 Induced Nausea and Vomiting (US) Denosumab Rheumatoid Arthritis Phase 3 (JP) TLR* FY2015 Q4 Ischemic Cerebrovascular Disease Pra

  22. Slide 22: Major R&D Pipeline

    Major R&D Pipeline As of January 2016 Therapeutic area Phase 1 Phase 2 Phase 3 Application  DS-1040  CS-3150 (JP)  Prasugrel (JP)  Edoxaban (ASCA etc.) (Acute ischemic stroke / TAFIa inhibitor) (Hypertension ・ DM nephropathy / (CS-747 / Ischemic stroke / Anti- (DU-176b / AF / oral factor Xa inhi

  23. Slide 23: Mid-term Business Plan

    Mid-term Business Plan  Date: March 31, 2016, Thursday For media representatives PM1:30-PM3:00 For investors and securities analysts PM4:00-PM5:30 *On-demand broadcasting will be available on later day  Location: Daiichi Sankyo Co., Ltd. Nihonbashi HQ  Speaker: Joji Nakayama, president and CEO

  24. Slide 24: Contact address regarding this material

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Financial forecasts, future projections and R&D information that Daiichi Sankyo discloses may include information that might be classified as “Forward Looking Statement”. These f

Daiichi Sankyo Company — Q3 FY2015 Earnings Presentation on 6ix